Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 324

1.

First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.

Chen Y, Yang J, Li X, Hao D, Wu X, Yang Y, He C, Wang W, Wang J.

Cancer Sci. 2016 Dec;107(12):1800-1805. doi: 10.1111/cas.13079. Epub 2016 Nov 25.

2.
3.

A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer.

Cai L, Zhu JF, Zhang XW, Lin SX, Su XD, Lin P, Chen K, Zhang LJ.

J Neurooncol. 2014 Nov;120(2):423-30. doi: 10.1007/s11060-014-1570-7. Epub 2014 Aug 7.

4.

Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.

Magnuson WJ, Lester-Coll NH, Wu AJ, Yang TJ, Lockney NA, Gerber NK, Beal K, Amini A, Patil T, Kavanagh BD, Camidge DR, Braunstein SE, Boreta LC, Balasubramanian SK, Ahluwalia MS, Rana NG, Attia A, Gettinger SN, Contessa JN, Yu JB, Chiang VL.

J Clin Oncol. 2017 Apr 1;35(10):1070-1077. doi: 10.1200/JCO.2016.69.7144. Epub 2017 Jan 23.

PMID:
28113019
5.

Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients.

Hsiao SH, Lin HC, Chou YT, Lin SE, Kuo CC, Yu MC, Chung CL.

Lung Cancer. 2013 Sep;81(3):455-461. doi: 10.1016/j.lungcan.2013.06.004. Epub 2013 Jul 18.

PMID:
23871711
6.

Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.

Tseng YH, Tseng YC, Lin YH, Lee YC, Perng RP, Whang-Peng J, Chen YM.

Oncologist. 2015 Jul;20(7):758-66. doi: 10.1634/theoncologist.2014-0352. Epub 2015 Jun 8.

8.

Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.

Gerber NK, Yamada Y, Rimner A, Shi W, Riely GJ, Beal K, Yu HA, Chan TA, Zhang Z, Wu AJ.

Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):322-9. doi: 10.1016/j.ijrobp.2014.02.022. Epub 2014 Mar 25.

9.

Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.

Iuchi T, Shingyoji M, Sakaida T, Hatano K, Nagano O, Itakura M, Kageyama H, Yokoi S, Hasegawa Y, Kawasaki K, Iizasa T.

Lung Cancer. 2013 Nov;82(2):282-7. doi: 10.1016/j.lungcan.2013.08.016. Epub 2013 Aug 28.

PMID:
24021541
10.

Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.

Magnuson WJ, Yeung JT, Guillod PD, Gettinger SN, Yu JB, Chiang VL.

Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):673-9. doi: 10.1016/j.ijrobp.2016.01.037. Epub 2016 Feb 2.

PMID:
27034176
11.

Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Jain A, Lim C, Gan EM, Ng DZ, Ng QS, Ang MK, Takano A, Chan KS, Tan WM, Kanesvaran R, Toh CK, Loo CM, Hsu AA, Devanand A, Lim CH, Koong HN, Koh T, Fong KW, Yap SP, Kim SW, Chowbay B, Oon L, Lim KH, Lim WT, Tan EH, Tan DS.

PLoS One. 2015 May 8;10(5):e0123587. doi: 10.1371/journal.pone.0123587. eCollection 2015.

12.

Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.

Doherty MK, Korpanty GJ, Tomasini P, Alizadeh M, Jao K, Labbé C, Mascaux CM, Martin P, Kamel-Reid S, Tsao MS, Pintilie M, Liu G, Bradbury PA, Feld R, Leighl NB, Chung C, Shepherd FA.

Radiother Oncol. 2017 May;123(2):195-202. doi: 10.1016/j.radonc.2017.03.007. Epub 2017 Mar 28.

PMID:
28363487
13.

Concurrent versus sequential whole brain radiotherapy and TKI in EGFR-mutated NSCLC patients with brain metastasis: A single institution retrospective analysis.

Chen H, Wu A, Tao H, Yang D, Luo Y, Li S, Yang Z, Chen M.

Medicine (Baltimore). 2018 Nov;97(44):e13014. doi: 10.1097/MD.0000000000013014.

14.

Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases.

Li SH, Liu CY, Hsu PC, Fang YF, Wang CC, Kao KC, Tseng LC, Yang CT.

Expert Rev Anticancer Ther. 2018 Jan;18(1):81-89. doi: 10.1080/14737140.2018.1409623. Epub 2017 Dec 2. Erratum in: Expert Rev Anticancer Ther. 2018 Mar;18(3):1.

PMID:
29172778
15.

Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.

Byeon S, Ham JS, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.

Med Oncol. 2016 Aug;33(8):97. doi: 10.1007/s12032-016-0811-3. Epub 2016 Jul 22.

16.

[Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis].

Chen L, Fu M, Zhou J, Yao Y, Zhou J.

Zhongguo Fei Ai Za Zhi. 2019 May 20;22(5):312-318. doi: 10.3779/j.issn.1009-3419.2019.05.08. Chinese.

17.

Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study.

Zeng YD, Zhang L, Liao H, Liang Y, Xu F, Liu JL, Dinglin XX, Chen LK.

Asian Pac J Cancer Prev. 2012;13(3):909-14.

18.

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib.

Yuan Y, Tan C, Li M, Shen H, Fang X, Hu Y, Ma S.

World J Surg Oncol. 2012 Nov 7;10:235. doi: 10.1186/1477-7819-10-235.

19.

Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.

Kim MH, Kim HR, Cho BC, Bae MK, Kim EY, Lee CY, Lee JS, Kang DR, Kim JH.

Lung Cancer. 2014 May;84(2):196-202. doi: 10.1016/j.lungcan.2014.01.022. Epub 2014 Feb 3.

PMID:
24629638
20.

Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC).

Zhu Q, Sun Y, Cui Y, Ye K, Yang C, Yang D, Ma J, Liu X, Yu J, Ge H.

Oncotarget. 2017 Feb 21;8(8):13304-13311. doi: 10.18632/oncotarget.14515.

Supplemental Content

Support Center